Dana Investment Advisors Inc. Has $2.51 Million Holdings in Natus Medical Incorporated (BABY)
Dana Investment Advisors Inc. grew its holdings in Natus Medical Incorporated (NASDAQ:BABY) by 18.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 66,903 shares of the medical equipment provider’s stock after buying an additional 10,409 shares during the quarter. Dana Investment Advisors Inc. owned approximately 0.21% of Natus Medical worth $2,509,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in the company. Koch Industries Inc. increased its position in Natus Medical by 7,423.5% in the second quarter. Koch Industries Inc. now owns 462,472 shares of the medical equipment provider’s stock worth $450,000 after purchasing an additional 456,325 shares during the period. Hillcrest Asset Management LLC acquired a new stake in Natus Medical in the third quarter worth about $8,966,000. Daruma Capital Management LLC increased its position in Natus Medical by 13.1% in the second quarter. Daruma Capital Management LLC now owns 1,470,839 shares of the medical equipment provider’s stock worth $54,862,000 after purchasing an additional 169,890 shares during the period. Marshall Wace North America L.P. acquired a new stake in Natus Medical in the second quarter worth about $5,832,000. Finally, Dimensional Fund Advisors LP increased its position in Natus Medical by 10.8% in the second quarter. Dimensional Fund Advisors LP now owns 1,552,938 shares of the medical equipment provider’s stock worth $57,924,000 after purchasing an additional 151,372 shares during the period. Institutional investors own 94.39% of the company’s stock.
A number of brokerages recently commented on BABY. BidaskClub lowered Natus Medical from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. Zacks Investment Research upgraded Natus Medical from a “hold” rating to a “buy” rating and set a $45.00 target price for the company in a research report on Tuesday, October 24th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $46.50.
In other Natus Medical news, VP Dong Chune Christopher Chung sold 12,642 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $42.91, for a total transaction of $542,468.22. Following the transaction, the vice president now owns 141,414 shares of the company’s stock, valued at approximately $6,068,074.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William M. Moore sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $41.01, for a total value of $205,050.00. The disclosure for this sale can be found here. Insiders own 5.50% of the company’s stock.
Natus Medical Incorporated (BABY) opened at $39.20 on Friday. Natus Medical Incorporated has a 1-year low of $31.65 and a 1-year high of $43.60. The company has a current ratio of 4.21, a quick ratio of 3.36 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $1,232.15, a PE ratio of 25.52 and a beta of 0.84.
Natus Medical (NASDAQ:BABY) last released its quarterly earnings data on Wednesday, October 25th. The medical equipment provider reported $0.40 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.38 by $0.02. Natus Medical had a positive return on equity of 12.06% and a negative net margin of 0.62%. The business had revenue of $122.60 million for the quarter, compared to analysts’ expectations of $122.41 million. During the same quarter in the previous year, the business posted $0.39 EPS. Natus Medical’s revenue for the quarter was up 34.9% on a year-over-year basis. analysts forecast that Natus Medical Incorporated will post 1.74 earnings per share for the current fiscal year.
Natus Medical Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.